Integrin VLA-5 and FAK are good targets to improve treatment response in the Philadelphia chromosome positive acute lymphoblastic leukemia

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Hu, Zhongbo ^a   Slayton, William B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Bone marrow microenvironment; Focal adhesion kinase; Integrin a5 1; Philadelphia chromosome; TAE226; Tyrosine kinase inhibitor

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; FIBRONECTIN; FOCAL ADHESION KINASE; LENTIVIRUS VECTOR; NILOTINIB; SHORT HAIRPIN RNA; VERY LATE ACTIVATION ANTIGEN 5;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IC 50; IMAGING; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MOUSE; MTT ASSAY; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84904673967     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00112     Document Type: Article

References (28)

1. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res (2006) 66:5387-93. doi: 10.1158/0008-5472.CAN-05-3058
2. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, et al. A function blocking anti-mouse integrin a5ß1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med (2007) 5:61. doi:10.1186/1479-5876-5-61
3. Stagno F, Cacciola E, Guglielmo P, Cacciola RR, Cacciola E. VLA-4 and VLA-5 integrin expression in adult acute lymphoblastic leukemia. Exp Hematol (1996) 24(4):493.
4. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest (1996) 98(2):521-8. doi:10.1172/JCI118820
5. De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert L, Payrastre B, et al. A new a5ß1 integrin-dependent survival pathway through GSK3ß activation in leukemic cells. PLoS One (2010) 5(3):e9807. doi:10.1371/journal.pone.0009807
6. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol (2000) 2:249-56. doi:10.1038/35010517
7. Sakurama K, Noma K, Takaoka M, Tomono Y, Watanabe N, Hatakeyama S, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther (2009) 8:127-34. doi:10.1158/1535-7163.MCT-08-0884
8. Yin B. Focal adhesion kinase as a target in the treatment of hematological malignancies. Leuk Res (2011) 35:1416-8. doi:10.1016/j.leukres.2011.04.017
9. Andersson S, D'Arcy P, Larsson O, Sehat B. Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor. Biochem Biophys Res Commun (2009) 387:36-41. doi:10.1016/j.bbrc.2009.06.088
10. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol (1995) 23:1153-9.
11. Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, et al. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am J Hematol (2009) 84:273-8. doi:10.1002/ajh.21381
12. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol (2011) 4:6. doi:10.1186/1756-8722-4-6
13. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, et al. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res (2005) 65(21):9962-70. doi:10.1158/0008-5472.CAN-05-1068
14. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem (1993) 268:1958-65.
15. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition. Cell Adhes Commun (1994) 2:491-501. doi:10.3109/15419069409014213
16. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther (2007) 6:1357-67. doi:10.1158/1535-7163.MCT-06-0476
17. Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep (2008) 20:1473-7. doi:10.3892/or_00000168
18. Sison EA, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol (2011) 4(3):271-83. doi:10.1586/ehm.11.30
19. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation. Leukemia (2001) 15(8):1232-9. doi:10.1038/sj.leu.2402179
20. van derLoo JC, Xiao X, McMillin D, Hashino K, Kato I, Williams DA. VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin. J Clin Invest (1998) 102(5):1051-61. doi:10.1172/JCI3687
21. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract (2012) 2012:283181. doi:10.1155/2012/283181
22. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with a4ß1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia (1999) 13:266-74. doi:10.1038/sj.leu.2401275
23. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood (2013) 121(10):1814-8. doi:10.1182/blood-2012-01-406272
24. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med (2003) 9:1158-65. doi:10.1038/nm909
25. Lundström A, Holmbom J, Lindqvist C, Nordström T. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun (1998) 250:735-40. doi:10.1006/bbrc.1998.9389
26. Desgrosellier J, Cheresh D. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 10:9-22. doi:10.1038/nrc2748
27. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 46(6):488-96. doi:10.1002/mc.20297
28. Ozkal S, Paterson JC, Tedoldi S, Hansmann ML, Kargi A, Manek S, et al. Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues. Pathol Res Pract (2009) 11:781-8. doi:10.1016/j.prp.2009.07.002